Targaba5 mg

Targaba is a gabapentinoid (alpha-2-delta calcium channel ligand) used in the management of neuropathic pain. Its use can be classified by strength of evidence as follows:

Established / Guideline-Supported Uses

• Peripheral neuropathic pain, including diabetic peripheral neuropathic pain (DPNP) - an approved indication for Targaba in several Asian regulatory markets, based on randomized controlled trials.
• Postherpetic neuralgia (PHN) - pain persisting after resolution of herpes zoster (shingles) rash, an approved indication for Targaba where the drug is registered.

Regulatory Status

Targaba is approved and marketed in Japan, South Korea, and other Asian markets (including Bangladesh) for peripheral neuropathic pain. It does not currently hold FDA approval in the United States; prescribing decisions outside markets where it is registered should follow local regulatory labeling.

As with other gabapentinoids, Targaba should be used only for indications supported by a physician's assessment of the patient's pain condition; it is not indicated for nociceptive (non-neuropathic) pain.

Mirogabalin Besylate is the besylate (benzenesulfonate) salt of mirogabalin, formulated as immediate-release oral tablets. In markets where it is available, including Bangladesh, Mirogabalin Besylate is supplied as film-coated tablets in strengths of 2.5 mg, 5 mg, 10 mg, and 15 mg (expressed as mirogabalin base equivalent).

Targaba is a small-molecule gabapentinoid that selectively binds to the alpha-2-delta (α2δ) subunit of voltage-gated calcium channels in the central nervous system. It belongs to the same pharmacological family as gabapentin and pregabalin but has a higher binding affinity and slower dissociation from the α2δ-1 subunit associated with analgesic effect, with comparatively lower affinity for the α2δ-2 subunit linked to some CNS side effects.

Targaba is used clinically for neuropathic pain conditions such as diabetic peripheral neuropathic pain and postherpetic neuralgia, and is taken orally, typically twice daily, with dose titrated to effect and tolerability.

Targaba belongs to the gabapentinoid class of medicines, also described as alpha-2-delta (α2δ) calcium channel ligands. This class also includes gabapentin and pregabalin, and is used primarily for neuropathic pain and, for related agents, certain seizure disorders.

Mechanism of Action

Mirogabalin Besylate binds selectively and with high affinity to the α2δ-1 and α2δ-2 auxiliary subunits of voltage-gated calcium channels, predominantly in the dorsal horn of the spinal cord and dorsal root ganglia. This binding reduces calcium influx at nerve terminals, which decreases the release of excitatory neurotransmitters (such as glutamate, noradrenaline, and substance P) at synapses of hyperexcitable neurons. Mirogabalin Besylate does not bind to GABA-A, GABA-B, or benzodiazepine receptors, and is not thought to act directly on sodium channels.

Pharmacokinetics

Because Mirogabalin Besylate is cleared mainly by the kidneys, dose adjustment is required in patients with renal impairment (see Dosage and Administration).

Targaba is for oral use only. Take each dose at approximately the same time every day, twice daily as directed, with or without food. Swallow the tablet whole with water. Do not stop taking Targaba suddenly without consulting your physician, as abrupt discontinuation may cause withdrawal-like symptoms such as insomnia, nausea, diarrhea, or reduced appetite; when stopping treatment, the dose should be gradually reduced over at least one week. If a dose of Targaba is missed, take it as soon as remembered unless it is close to the time of the next dose, in which case the missed dose should be skipped - do not double the dose.

Clinically significant interactions with Targaba include:

• Central nervous system (CNS) depressants (e.g., opioids, benzodiazepines such as lorazepam, other sedatives, and alcohol): Concurrent use with Targaba produces additive CNS depression, increasing the risk of sedation, dizziness, respiratory depression, and impaired attention/motor coordination. Concomitant use should be avoided where possible and monitored closely if necessary.
• Probenecid: Inhibits renal transporters involved in clearance of Targaba, increasing mirogabalin exposure (Cmax and AUC); dose adjustment or closer monitoring may be needed.
• Cimetidine: Modestly increases plasma concentrations of Targaba via effects on renal elimination; clinical significance is generally limited, but monitoring is reasonable when combined with other interacting drugs.

Patients should inform their physician or pharmacist of all medicines, supplements, and alcohol use before starting Targaba.

Adverse effects of Targaba are generally dose-related and most prominent during titration.

Common

• Somnolence (sleepiness) and dizziness
• Peripheral edema (swelling of hands, ankles, or feet)
• Weight gain
• Constipation
• Blurred or double vision

Less Common but Clinically Important

• Headache, tremor, memory impairment, or unsteady gait
• Orthostatic hypotension (dizziness on standing)
• Rare reports of loss of consciousness
• Hallucinations or confusion (more common in elderly patients)
• Signs of liver dysfunction (yellowing of skin/eyes, dark urine) - rare but requires prompt evaluation

Patients should seek medical attention promptly for severe dizziness, fainting, difficulty breathing, signs of an allergic reaction, or signs of liver problems while taking Targaba.

Pregnancy: Data on the use of Targaba in human pregnancy are limited. Animal reproduction studies indicate that mirogabalin crosses the placenta. Targaba should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus, and only under the guidance of a physician. Women of childbearing potential should discuss effective contraception with their physician while taking Targaba.

Lactation: It is not known whether mirogabalin passes into human breast milk in clinically significant amounts, though transfer into milk has been observed in animal studies. Because of the potential for sedation or other adverse effects in a nursing infant, breastfeeding is generally not recommended during treatment with Targaba unless a physician determines that the benefit outweighs the risk; consult a physician before breastfeeding while using this medicine.

• Somnolence and dizziness: Targaba commonly causes sleepiness, dizziness, and blurred vision, particularly during dose initiation and titration. Patients should avoid driving, operating heavy machinery, or performing other hazardous tasks until they know how Targaba affects them.
• Additive CNS depression: Concomitant use of alcohol, opioids, benzodiazepines, or other CNS depressants with Targaba increases the risk of sedation and respiratory depression (see Interactions).
• Peripheral edema: Swelling of the extremities may occur and should be monitored, particularly in patients with pre-existing cardiovascular disease.
• Discontinuation/withdrawal: Targaba should not be stopped abruptly. Sudden discontinuation may precipitate withdrawal-like symptoms (insomnia, nausea, diarrhea, decreased appetite, anxiety). Taper the dose gradually over at least one week under medical supervision.
• Potential for misuse: As with other gabapentinoids, there is a recognized signal for misuse or dependence with Targaba, particularly in patients with a history of substance use disorder, although this risk is generally considered lower than with opioids. Use with caution and appropriate monitoring in such patients.
• Renal/hepatic impairment: Dose adjustment is required in renal impairment (see Dosage and Administration); use with caution in hepatic impairment.
• Elderly patients: Increased susceptibility to dizziness, somnolence, and falls; use caution and consider more gradual titration.
• Weight gain: Monitor weight during treatment; advise on diet and activity if significant weight gain occurs.

Reported symptoms of Targaba overdose may include marked somnolence, dizziness, confusion, dysarthria (slurred speech), euphoric mood, and impaired coordination. There is no specific antidote for Targaba overdose.

If overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services. Management is supportive and symptomatic, and may include general measures to support vital functions. Hemodialysis removes only a small fraction of the drug and is generally not considered an effective primary treatment for overdose, though it may be considered by treating physicians in select clinical circumstances (e.g., significant renal impairment). Do not attempt to manage a suspected overdose of Targaba at home without professional medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

Dose reduction of Targaba is required based on the degree of renal impairment (see Dosage and Administration). Close monitoring is advised in patients with reduced kidney function, including those on dialysis.

Hepatic Impairment

Clinical experience with Targaba in significant hepatic impairment is limited; use with caution and monitor for adverse effects, including rare reports of liver dysfunction (see Side Effects).

Elderly

Elderly patients may be more susceptible to somnolence, dizziness, and edema with Targaba, increasing the risk of falls; consider more gradual dose titration and monitor closely.

Pregnancy and Lactation

See Pregnancy and Lactation section for detailed guidance.

Pediatric Patients

See Pediatric Use section - safety and efficacy of Targaba have not been established in children and adolescents.

The duration of treatment with Targaba is individualized based on the underlying condition, response to therapy, and tolerability, and should be determined by the prescribing physician. Pain relief may take several weeks of consistent dosing (including titration) to become fully apparent. Treatment is typically continued as long as it provides meaningful symptom benefit with an acceptable side-effect profile, with periodic physician reassessment. When discontinuation is planned, Targaba should be tapered gradually rather than stopped abruptly (see Precautions and Warnings).

Gabapentinoid; Alpha-2-delta (α2δ) calcium channel ligand; Neuropathic pain agent

Mirogabalin Besylate selectively and with high affinity binds the α2δ-1 and α2δ-2 auxiliary subunits of voltage-gated calcium channels on hyperexcitable neurons, reducing calcium influx at nerve terminals. This decreases release of excitatory neurotransmitters (glutamate, noradrenaline, substance P) involved in pain signal transmission, thereby reducing neuropathic pain, without direct action on GABA receptors or sodium channels.

The safety and efficacy of Targaba in children and adolescents (below 18 years of age) have not been established. Targaba is therefore not recommended for use in pediatric patients outside of a clinical trial setting, and should only be considered in this population under specialist guidance if no suitable alternative exists.